Last reviewed · How we verify
NCT05226416: ACTIV4
Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection
trial in COVID-19 in 3,554 participants. Completed in 21 April 2023.
31 March 2022
Quick facts
| Lead sponsor | Eurasian Association of Therapists |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,554 |
| Start date | 21 February 2022 |
| Primary completion | 31 March 2022 |
| Estimated completion | 21 April 2023 |
| Sites | 1 location across Russia |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Eurasian Association of Therapists
Who can join
18 and older, any sex, with COVID-19 or Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depersonalized multi-centered registry initiated to analyze dynamics of non-infectious diseases after SARS-CoV-2 infection in population of Eurasian adult patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05226416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Eurasian Association of Therapists trials
Trials by the same sponsor.
- NCT05690009 — Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease · completed
- NCT04295057 — Register of Therapeutical Patients Over 60 Years · unknown
- NCT05189847 — Clinical Register Studying the therApeutic Patient Population With Multifocal Atherosclerosis · completed
- NCT04709120 — Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection · completed
- NCT04492384 — Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05226416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eurasian Association of Therapists
- Last refreshed: 9 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05226416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing